{"id":33067,"date":"2025-08-12T17:11:16","date_gmt":"2025-08-12T11:41:16","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=33067"},"modified":"2025-08-12T17:11:18","modified_gmt":"2025-08-12T11:41:18","slug":"pharma-news-boehringer-genmab-tiziana","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-boehringer-genmab-tiziana","title":{"rendered":"Teva\u2019s AJOVY Expanded by FDA as First Anti-CGRP Preventive for Pediatric Episodic Migraine; NRx Pharma\u2019s NRX-100 Granted FDA Fast Track for Suicidal Ideation in Depression\/Bipolar Depression; Boehringer Ingelheim\u2019s HERNEXEOS Wins FDA Accelerated Approval for HER2-Mutant Advanced NSCLC; Genmab\u2019s Phase III EPCORE FL-1 Meets Dual Endpoints in Relapsed\/Refractory Follicular Lymphoma; Tiziana\u2019s Phase II IND Cleared by FDA for Multiple System Atrophy"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69e34a159c895\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69e34a159c895\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-boehringer-genmab-tiziana\/#FDA_Expands_Tevas_AJOVY_As_First_Anti-CGRP_Preventive_For_Pediatric_Episodic_Migraine\" >FDA Expands Teva\u2019s AJOVY As First Anti-CGRP Preventive For Pediatric Episodic Migraine<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-boehringer-genmab-tiziana\/#NRx_Pharma_Gets_FDA_Fast_Track_For_NRX-100_In_Suicidal_Ideation_With_DepressionBipolar_Depression\" >NRx Pharma Gets FDA Fast Track For NRX-100 In Suicidal Ideation With Depression\/Bipolar Depression<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-boehringer-genmab-tiziana\/#Boehringer_Ingelheim_Gains_FDA_Accelerated_Nod_For_HERNEXEOS_In_HER2-Mutant_Advanced_NSCLC\" >Boehringer Ingelheim Gains FDA Accelerated Nod For HERNEXEOS In HER2-Mutant Advanced NSCLC<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-boehringer-genmab-tiziana\/#Genmabs_Phase_III_EPCORE_FL-1_Meets_Dual_Endpoints_In_RelapsedRefractory_Follicular_Lymphoma\" >Genmab\u2019s Phase III EPCORE FL-1 Meets Dual Endpoints In Relapsed\/Refractory Follicular Lymphoma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-boehringer-genmab-tiziana\/#FDA_Clears_Tizianas_Phase_II_IND_For_Multiple_System_Atrophy\" >FDA Clears Tiziana\u2019s Phase II IND For Multiple System Atrophy<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-expands-teva-s-ajovy-as-first-anti-cgrp-preventive-for-pediatric-episodic-migraine\"><span class=\"ez-toc-section\" id=\"FDA_Expands_Tevas_AJOVY_As_First_Anti-CGRP_Preventive_For_Pediatric_Episodic_Migraine\"><\/span>FDA Expands Teva\u2019s AJOVY As First Anti-CGRP Preventive For Pediatric Episodic Migraine<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Teva Pharmaceuticals<\/strong>, a U.S. affiliate of <strong>Teva Pharmaceutical Industries Ltd.,<\/strong> announced that the FDA has approved <strong>AJOVY (fremanezumab-vfrm)<\/strong> for the preventive <a href=\"https:\/\/www.delveinsight.com\/report-store\/migraine-market\"><strong>treatment of<\/strong> <strong>episodic migraine<\/strong><\/a> in children and adolescents aged 6\u201317 years who weigh at least 45 kg (99 lbs). This approval makes AJOVY the first and only calcitonin gene-related peptide (CGRP) antagonist indicated for both pediatric episodic migraine prevention and migraine prevention in adults, expanding access across age groups.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cMigraines are a common yet invisible condition that can severely disrupt daily life for children and adolescents,\u201d said Chris Fox, Executive Vice President, U.S. Commercial and Innovative Franchise Lead and Head of Global Marketing Business at Teva. \u201cWith this FDA approval, AJOVY now offers younger patients a new treatment option, addressing a long-standing gap in care and offering families added support as they navigate the challenges of this condition.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>AJOVY, already approved in the U.S. since 2018 for adults, is administered once monthly and can be given in-office or at home. The single-dose injection offers a practical option intended to improve adherence and reduce treatment burden for families managing pediatric migraine\u2014a condition affecting an estimated 1 in 10 children and adolescents in the U.S., often resulting in missed school days and social disruption.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cPediatric migraine is a complex condition that can significantly impact a child\u2019s daily life, from school performance to emotional well-being,\u201d said Dr. Jennifer McVige, Pediatric Neurologist at the DENT Neurologic Institute. \u201cHaving an FDA-approved treatment like AJOVY provides a targeted preventive approach that can help reduce the frequency of attacks in younger patients and help clinicians better manage this often-overlooked condition.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-nrx-pharma-gets-fda-fast-track-for-nrx-100-in-suicidal-ideation-with-depression-bipolar-depression\"><span class=\"ez-toc-section\" id=\"NRx_Pharma_Gets_FDA_Fast_Track_For_NRX-100_In_Suicidal_Ideation_With_DepressionBipolar_Depression\"><\/span>NRx Pharma Gets FDA Fast Track For NRX-100 In Suicidal Ideation With Depression\/Bipolar Depression<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>NRx Pharmaceuticals, Inc.<\/strong> announced that the FDA has granted Fast Track designation to <strong>NRX-100 <\/strong>for the treatment of <strong>suicidal ideation<\/strong> in patients with <strong>depression<\/strong>, including<strong> <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/bipolar-disorder-manic-depression-market\"><strong>bipolar depression<\/strong><\/a><strong>. <\/strong>This decision expands the drug\u2019s addressable population tenfold compared to its 2017 designation, which covered only suicidal bipolar depression when used in combination with NRX-101. The designation also aligns NRX-100 with eligibility for the FDA\u2019s Accelerated Approval and the Commissioner\u2019s National Priority Voucher (CNPV) programs.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe thank FDA for its thoughtful review of our Fast Track designation request, and believe this regulatory determination is a significant step forward in our goal to address the national crisis of suicide among soldiers, first responders, veterans, and civilians alike,\u201d said Dr. Jonathan Javitt, Chairman and CEO of NRx Pharmaceuticals. \u201cLarge-scale government-supported trials have demonstrated a robust and statistically significant reduction in suicidal ideation and depression with administration of ketamine.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The FDA\u2019s decision was supported by multiple controlled trials showing NRX-100\u2019s significant impact on reducing suicidal ideation. In a Columbia University study, intravenous ketamine achieved a 55% response rate compared to 30% for the active comparator, while a French government-sponsored trial showed a 63% full remission rate within three days versus 31% with placebo. Unlike intranasal forms, these effects were achieved with intravenous administration.<\/p>\n\n\n\n<p>Under the Fast Track program, NRx plans to post an expanded access policy for NRX-100 within two weeks and request a meeting with FDA leadership to finalize its Accelerated Approval\/CNPV submission. The designation grants the company benefits such as enhanced FDA communication, rolling review, and potential priority review, potentially accelerating access for the estimated 13 million Americans who consider suicide each year.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-boehringer-ingelheim-gains-fda-accelerated-nod-for-hernexeos-in-her2-mutant-advanced-nsclc\"><span class=\"ez-toc-section\" id=\"Boehringer_Ingelheim_Gains_FDA_Accelerated_Nod_For_HERNEXEOS_In_HER2-Mutant_Advanced_NSCLC\"><\/span>Boehringer Ingelheim Gains FDA Accelerated Nod For HERNEXEOS In HER2-Mutant Advanced NSCLC<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Boehringer Ingelheim <\/strong>announced that the FDA has granted accelerated approval to <strong>HERNEXEOS (zongertinib tablets)<\/strong> for the treatment of adult patients with <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-non-small-cell-lung-cancer-market\"><strong>unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC)<\/strong><\/a><strong> <\/strong>harboring <strong>HER2 (ERBB2) <\/strong>tyrosine kinase domain activating mutations, as confirmed by an FDA-approved test, and who have received prior systemic therapy. The approval is based on objective response rate (ORR) and duration of response (DoR) data, with continued approval contingent upon confirmatory trial results.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWith the approval of zongertinib, we have an effective, targeted, orally administered treatment option for patients with HER2-mutant non-small cell lung cancer in the U.S. that not only elicits a durable response but, importantly, has a manageable safety profile,\u201d said Dr. John Heymach, MD, PhD, chair of Thoracic\/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center and coordinating investigator for the Beamion-LUNG 1 trial.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The FDA\u2019s decision follows results from the Phase Ib Beamion-LUNG 1 trial, where HERNEXEOS achieved a 75% ORR (N=71), including 6% complete responses and 69% partial responses, with a DoR of \u22656 months in 58% of patients. The therapy showed a manageable safety profile with a 2.9% discontinuation rate; the most common adverse reactions included diarrhea, hepatotoxicity, rash, fatigue, and nausea.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe are grateful to bring forward HERNEXEOS, which has the potential to reset the benchmark for those living with HER2-mutant advanced NSCLC, a condition associated with a particularly poor prognosis,\u201d said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. \u201cRecognizing its potential, we accelerated development to deliver this treatment to patients within four years of starting the first clinical trial.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-genmab-s-phase-iii-epcore-fl-1-meets-dual-endpoints-in-relapsed-refractory-follicular-lymphoma\"><span class=\"ez-toc-section\" id=\"Genmabs_Phase_III_EPCORE_FL-1_Meets_Dual_Endpoints_In_RelapsedRefractory_Follicular_Lymphoma\"><\/span>Genmab\u2019s Phase III EPCORE FL-1 Meets Dual Endpoints In Relapsed\/Refractory Follicular Lymphoma<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Genmab A\/S<\/strong> announced that the <strong>Phase III EPCORE\u00ae FL-1 trial <\/strong>of subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) met its dual primary endpoints in adult <a href=\"https:\/\/www.delveinsight.com\/report-store\/follicular-lymphoma-market-insights\"><strong>patients with relapsed or refractory (R\/R) follicular lymphoma (FL)<\/strong>.<\/a> The regimen significantly improved overall response rate (ORR) and progression-free survival (PFS), reducing the risk of disease progression or death by 79% compared to R2 alone. Data from this pre-planned interim analysis will be presented at the American Society of Hematology (ASH) Annual Meeting and will form the basis for global regulatory submissions.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWhile therapeutic options exist for patients with relapsed or refractory follicular lymphoma, response rates tend to decline and durability diminishes with each subsequent line of treatment,\u201d said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. \u201cThe results from this trial, and the FDA\u2019s acceptance of our sBLA for priority review, demonstrate the potential of this epcoritamab combination therapy to reshape the treatment landscape.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The FDA has accepted for priority review a supplemental Biologics License Application (sBLA) for epcoritamab plus R2 following at least one prior systemic therapy, with a target action date of November 30, 2025. The application is supported by data showing an ORR of 95.7% and a hazard ratio for PFS of 0.21 in the intent-to-treat population. If approved, it would become the first bispecific antibody combination regimen available in the U.S. as a second-line option for R\/R FL.<\/p>\n\n\n\n<p>The safety profile of the combination was consistent with known profiles of epcoritamab and R2, with no new safety signals observed. Epcoritamab is already approved in the U.S. as a single agent for R\/R FL after two or more prior systemic therapies and has received Breakthrough Therapy Designation in combination with R2 for this indication.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-clears-tiziana-s-phase-ii-ind-for-multiple-system-atrophy\"><span class=\"ez-toc-section\" id=\"FDA_Clears_Tizianas_Phase_II_IND_For_Multiple_System_Atrophy\"><\/span>FDA Clears Tiziana\u2019s Phase II IND For Multiple System Atrophy<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Tiziana Life Sciences, Ltd., <\/strong>announced that the FDA has approved its<strong> Investigational New Drug (IND) <\/strong>application for a phase IIa trial evaluating intranasal foralumab in <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-system-atrophy-msa-market\"><strong>patients with Multiple System Atrophy (MSA)<\/strong><\/a><strong>,<\/strong> a rare and rapidly progressive neurodegenerative disorder with no approved treatments. The six-month, open-label study (NCT06868628) will assess foralumab\u2019s effects on microglial activation, clinical outcomes, and safety in MSA patients through eight 3-week dosing cycles.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe are pleased that the FDA has approved the IND to treat MSA patients with nasal foralumab,\u201d said Vikram Khurana, MD, PhD, Division Chief of Movement Disorders and Director of the MSA Center of Excellence at Brigham and Women\u2019s Hospital. \u201cNeuroinflammation plays a significant role in MSA\u2019s rapid progression. Intranasal foralumab offers a novel therapeutic pathway by targeting T-cell mediated immune activation in the brain.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Foralumab, a fully human anti-CD3 monoclonal antibody, is designed to induce regulatory T cells and modulate T-cell-driven inflammation, potentially slowing neuronal damage in neurodegenerative diseases. The therapy\u2019s intranasal delivery aims to engage immune regulation while minimizing systemic immune suppression.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Ivor Elrifi, CEO of Tiziana Life Sciences, added, \u201cIts ability to reduce microglial activation presents a promising therapeutic strategy for MSA as well as other neuroinflammatory diseases such as Multiple Sclerosis, Alzheimer\u2019s Disease, and ALS. This approach could represent a meaningful step toward addressing significant unmet medical needs in these patient populations.\u201d<\/em><\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>FDA Expands Teva\u2019s AJOVY As First Anti-CGRP Preventive For Pediatric Episodic Migraine Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the FDA has approved AJOVY (fremanezumab-vfrm) for the preventive treatment of episodic migraine in children and adolescents aged 6\u201317 years who weigh at least 45 kg (99 lbs). This approval makes [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":33068,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[22033,16811,204,704,18834,18833,20048,349,1193,6440,6439,18082,20778,20779,20781,420,6733,979,12555,6732,12557,639,5789,2267],"industry":[17225],"therapeutic_areas":[17245,17228],"class_list":["post-33067","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-bipolar-depression","tag-bipolar-depression-market","tag-delveinsight","tag-fda","tag-follicular-lymphoma","tag-follicular-lymphoma-market","tag-follicular-lymphoma-treatment","tag-latest-pharma-news","tag-migraine","tag-migraine-market","tag-migraine-treatment","tag-migraine-treatment-market","tag-multiple-system-atrophy","tag-multiple-system-atrophy-treatment","tag-multiple-system-atrophy-treatment-market","tag-news","tag-non-small-cell-lung-cancer","tag-non-small-cell-lung-cancer-nsclc","tag-non-small-cell-lung-cancer-market","tag-non-small-cell-lung-cancer-pipeline","tag-non-small-cell-lung-cancer-treatment-market","tag-pharma-news","tag-recent-pharma-news","tag-refractory-follicular-lymphoma","industry-pharmaceutical","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>pharma-news-for-boehringer-genmab-tiziana<\/title>\n<meta name=\"description\" content=\"Teva\u2019s AJOVY; NRx Pharma\u2019s NRX-100; Boehringer Ingelheim\u2019s HERNEXEOS; Genmab\u2019s EPCORE FL-1; Tiziana\u2019s Multiple System Atrophy Therapy\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-boehringer-genmab-tiziana\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"pharma-news-for-boehringer-genmab-tiziana\" \/>\n<meta property=\"og:description\" content=\"Teva\u2019s AJOVY; NRx Pharma\u2019s NRX-100; Boehringer Ingelheim\u2019s HERNEXEOS; Genmab\u2019s EPCORE FL-1; Tiziana\u2019s Multiple System Atrophy Therapy\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-boehringer-genmab-tiziana\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-12T11:41:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-12T11:41:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/08\/12171101\/12-8-2025-feature.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"pharma-news-for-boehringer-genmab-tiziana","description":"Teva\u2019s AJOVY; NRx Pharma\u2019s NRX-100; Boehringer Ingelheim\u2019s HERNEXEOS; Genmab\u2019s EPCORE FL-1; Tiziana\u2019s Multiple System Atrophy Therapy","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-boehringer-genmab-tiziana","og_locale":"en_US","og_type":"article","og_title":"pharma-news-for-boehringer-genmab-tiziana","og_description":"Teva\u2019s AJOVY; NRx Pharma\u2019s NRX-100; Boehringer Ingelheim\u2019s HERNEXEOS; Genmab\u2019s EPCORE FL-1; Tiziana\u2019s Multiple System Atrophy Therapy","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-boehringer-genmab-tiziana","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-08-12T11:41:16+00:00","article_modified_time":"2025-08-12T11:41:18+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/08\/12171101\/12-8-2025-feature.webp","type":"image\/webp"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-boehringer-genmab-tiziana","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-boehringer-genmab-tiziana","name":"pharma-news-for-boehringer-genmab-tiziana","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-boehringer-genmab-tiziana#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-boehringer-genmab-tiziana#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/08\/12171101\/12-8-2025-feature.webp","datePublished":"2025-08-12T11:41:16+00:00","dateModified":"2025-08-12T11:41:18+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Teva\u2019s AJOVY; NRx Pharma\u2019s NRX-100; Boehringer Ingelheim\u2019s HERNEXEOS; Genmab\u2019s EPCORE FL-1; Tiziana\u2019s Multiple System Atrophy Therapy","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-boehringer-genmab-tiziana"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-boehringer-genmab-tiziana#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/08\/12171101\/12-8-2025-feature.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/08\/12171101\/12-8-2025-feature.webp","width":772,"height":482,"caption":"pharma-news-for-boehringer-genmab-tiziana"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/08\/12171101\/12-8-2025-feature-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">bipolar depression<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bipolar depression market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Migraine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Migraine market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Migraine treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Migraine Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Multiple System Atrophy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Multiple System Atrophy Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Multiple System Atrophy Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer (NSCLC)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">refractory follicular lymphoma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">bipolar depression<\/span>","<span class=\"advgb-post-tax-term\">Bipolar depression market<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma Market<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma Treatment<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Migraine<\/span>","<span class=\"advgb-post-tax-term\">Migraine market<\/span>","<span class=\"advgb-post-tax-term\">Migraine treatment<\/span>","<span class=\"advgb-post-tax-term\">Migraine Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">Multiple System Atrophy<\/span>","<span class=\"advgb-post-tax-term\">Multiple System Atrophy Treatment<\/span>","<span class=\"advgb-post-tax-term\">Multiple System Atrophy Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer (NSCLC)<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Market<\/span>","<span class=\"advgb-post-tax-term\">Non-small cell lung cancer Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">refractory follicular lymphoma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 months ago","modified":"Updated 8 months ago"},"absolute_dates":{"created":"Posted on Aug 12, 2025","modified":"Updated on Aug 12, 2025"},"absolute_dates_time":{"created":"Posted on Aug 12, 2025 5:11 pm","modified":"Updated on Aug 12, 2025 5:11 pm"},"featured_img_caption":"pharma-news-for-boehringer-genmab-tiziana\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33067","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=33067"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33067\/revisions"}],"predecessor-version":[{"id":33069,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33067\/revisions\/33069"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/33068"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=33067"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=33067"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=33067"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=33067"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=33067"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}